NEW YORK--(BUSINESS WIRE)--CannRx Technology, Inc. (http://www.cannrx.com/), a privately-held Delaware corporation developing pharmaceutical-grade products from cannabis, announced today that Jeffrey Friedland, noted author, speaker, and opinion leader in the cannabis industry, has joined the Company’s Board of Directors.
Mr. Friedland is at the forefront of the global cannabis industry. His book, “Marijuana, the World's Most Misunderstood Plant”, has received much attention. Mr. Friedland was an owner of two Colorado marijuana retail stores and a grow facility that were featured in the CNN 2015 reality series, High Profits. In addition, he has been quoted in numerous publications, including Wall Street Journal, Reuters, the New York Times, Bloomberg Television and USA Today.
Mr. Friedland is also the CEO of the financial services firm, Friedland Global Capital (http://www.friedlandcapital.com/) which provides corporate finance and strategic advisory services. He has served as a CEO of a NASDAQ-listed company, a director of an NYSE-listed company and the chairman of a Frankfurt Stock Exchange-listed company.
Dr. William Levine, the CannRx’s Executive Chairman, commented on the announcement, “Jeff brings a breadth and depth of experience, in both the cannabis and financial markets, that will be invaluable to CannRx as we work to commercialize our growing platform of products and technologies. Management is excited to work with him and I look forward to his contribution.”
Mr. Friedland stated, “One of my primary concerns regarding medical cannabis is the limited ability to clearly define its indications and effects for medical practitioners and consumers, which often leads to inaccurate dosing, unpredictable clinical results and undesirable side effects. CannRx’s proprietary platform enables the establishment of standard protocols and therapies based upon specific conditions and symptoms - which I believe are critical to the broad acceptance of medical cannabis. Simply put, CannRx technology enables us to scientifically identify which cannabis strain to use for which diseases and how to dose it effectively. Something that the marijuana industry is sorely lacking.
“Equally important, CannRx is more than a research and development company, its objective is to generate near-term revenues through the licensing of its technologies in the U.S. to state-licensed medical marijuana businesses, while also seeking Food and Drug Administration approval for its cannabis-based pharmaceuticals which provides the opportunity for significant commercial success.”
About CannRx Technology
Initially formed as a subsidiary of Izun Pharma Corp. (“Izun”), CannRx has a unique technological advantage due to its relationship with Izun, a company with 16 years of success in the specialty pharma area of botanical medicine. Izun has several pharmaceutical products approved in Europe and the US.
